{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:24:44Z","timestamp":1761294284893},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,4,15]]},"DOI":"10.18632\/aging.202782","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T06:24:27Z","timestamp":1616826267000},"page":"10225-10239","source":"Crossref","is-referenced-by-count":8,"title":["Conditional survival and hazards of death for peripheral T-cell lymphomas"],"prefix":"10.18632","volume":"13","author":[{"given":"Hongye","family":"Gao","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqiang","family":"Ji","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Record Statistics, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Chaoyang 100021, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Haidian 100142, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"12","author":"Jaffe","year":"2016","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12185-014-1520-3","article-title":"Peripheral T cell lymphoma in Asia.","volume":"9","author":"Ko","year":"2014","journal-title":"Int J Hematol"},{"key":"3","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes.","volume":"2","author":"Weisenburger","year":"2008","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1746-1596-6-77","article-title":"Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution.","volume":"6","author":"Liu","year":"2011","journal-title":"Diagn Pathol"},{"key":"5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","article-title":"Mortality of lymphoma and myeloma in China, 2004-2017: an observational study.","volume":"1","author":"Zhu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes.","volume":"6","author":"Flowers","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"7","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1002\/cam4.3037","article-title":"Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades.","volume":"9","author":"Wu","year":"2020","journal-title":"Cancer Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017.","volume":"9","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"key":"9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1008200307625","article-title":"Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification.","volume":"8","author":"Burnelli","year":"1997","journal-title":"Ann Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials.","volume":"11","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.","volume":"12","author":"Tan","year":"2014","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/jamasurg.2015.0219","article-title":"Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients.","volume":"15","author":"Pawlik","year":"2015","journal-title":"JAMA Surg"},{"key":"13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/10543406.2017.1405012","article-title":"Statistical methods for conditional survival analysis.","volume":"2","author":"Chow","year":"2018","journal-title":"J Biopharm Stat"},{"key":"14","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1002\/cncr.28273","article-title":"Dynamic prognostication using conditional survival estimates.","volume":"11","author":"Panageas","year":"2013","journal-title":"Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia.","volume":"3","author":"Pickles","year":"2016","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/j.bbmt.2019.09.012","article-title":"Conditional long-term survival after autologous hematopoietic cell transplantation for diffuse large B cell lymphoma.","volume":"2","author":"Majhail","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"17","doi-asserted-by":"publisher","first-page":"e190194","DOI":"10.1001\/jamanetworkopen.2019.0194","article-title":"Risk-dependent conditional survival and failure hazard after radiotherapy for early-stage extranodal natural killer\/T-cell lymphoma.","volume":"2","author":"Qian","year":"2019","journal-title":"JAMA Netw Open"},{"key":"18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-019-0785-7","article-title":"Burden of lymphoma in China, 2006-2016: an analysis of the global burden of disease study 2016.","volume":"1","author":"Zhu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.","volume":"12","author":"Relander","year":"2014","journal-title":"Blood"},{"key":"20","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.","volume":"6","author":"Birkmann","year":"2016","journal-title":"Blood Cancer J"},{"key":"21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan.","volume":"3","author":"Ueda","year":"2017","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jjco\/hyi006","article-title":"Treatment outcome of angiocentric T-cell and NK\/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy.","volume":"3","author":"Park","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.","volume":"12","author":"Chim","year":"2012","journal-title":"Blood"},{"key":"24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hon.853","article-title":"Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.","volume":"2","author":"Hirano","year":"2008","journal-title":"Hematol Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets.","volume":"10","author":"Canioni","year":"2015","journal-title":"Haematologica"},{"key":"26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.","volume":"12","author":"Vose","year":"2017","journal-title":"Blood"},{"key":"27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1080\/10428194.2017.1393671","article-title":"Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.","volume":"5","author":"Wotherspoon","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"28","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.","volume":"3","author":"Savage","year":"2013","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.","volume":"11","author":"Weisenburger","year":"2008","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project.","volume":"1","author":"M\u00fcller-Hermelink","year":"2002","journal-title":"Ann Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/leu.2008.320","article-title":"Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.","volume":"2","author":"Dogan","year":"2009","journal-title":"Leukemia"},{"key":"32","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.","volume":"12","author":"Witzig","year":"2014","journal-title":"Blood"},{"key":"33","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma.","volume":"3","author":"Feldman","year":"2017","journal-title":"J Clin Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.","volume":"1","author":"Connors","year":"2004","journal-title":"Ann Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","article-title":"Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.","volume":"13","author":"Stelljes","year":"2018","journal-title":"Blood"},{"key":"36","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-cell lymphoma.","volume":"2","author":"Baugier de Materre","year":"2018","journal-title":"Oncologist"},{"key":"37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.","volume":"7","author":"Nielsen","year":"2014","journal-title":"J Hematol Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.","volume":"3","author":"Shustov","year":"2014","journal-title":"J Clin Oncol"},{"key":"39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/iwj.13265","article-title":"Approaches to the treatment of pilonidal sinus disease, clinical practice in 2019.","volume":"1","author":"Ramanathan","year":"2020","journal-title":"Int Wound J"},{"key":"40","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/tbj.14072","article-title":"Complete breast autoamputation: clinical image.","volume":"2","author":"Kurnaz","year":"2020","journal-title":"Breast J"},{"key":"41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma.","volume":"32","author":"International Non-Hodgkin","year":"1993","journal-title":"N Engl J Med"},{"key":"42","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI sponsored international working group.","volume":"1","author":"Hiddemann","year":"1999","journal-title":"J Clin Oncol"},{"key":"43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma.","volume":"2","author":"Lister","year":"2007","journal-title":"J Clin Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1200\/JCO.2009.23.0573","article-title":"Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.","volume":"2","author":"Wang","year":"2010","journal-title":"J Clin Oncol"},{"key":"45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/sim.5915","article-title":"Improved survival modeling in cancer research using a reduced piecewise exponential approach.","volume":"3","author":"Kim","year":"2014","journal-title":"Stat Med"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T16:55:56Z","timestamp":1620320156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,15]]}},"alternative-id":["202782","33819191"],"URL":"https:\/\/doi.org\/10.18632\/aging.202782","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]}}}